About MAVRIC-IPF

The goal of MAVRIC-IPF is to understand the use of Metformin to treat IPF. Researchers designed the study to see if Metformin can slow the disease progression of IPF.

We know that Metformin can lower blood sugar levels in patients with diabetes. Metformin may also have anti-fibrotic effects. That means anti-scarring effects in the lungs. Metformin is well-tolerated, inexpensive and has a long history of safe clinical use.

Some study participants will be given Metformin. Some study participants will be given a placebo, or an inactive version of medication. Study participants will not know whether they are given active Metformin or the inactive placebo medication. Participants will be randomly assigned to one of these options. 

Study participation lasts for up to two years. During this time clinical testing and measurements will be taken at multiple different in-person visits over the two-year study period.

Study participation is voluntary. A participant may leave the study at any time, for any reason.

The study coordinator will explain the risks and benefits to you. This information and more will be given to you as part of the informed consent process.

The information learned could help the IPF community. Thank you for your interest in MAVRIC-IPF.

MAVRIC-IPF is funded by the United States Department of Defense (DoD) Congressionally Directed Medical Research Programs (CDMRP).